Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?

Type 1 Diabetes Mellitus Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00472875
• Other study ID #: 07/Q0703/18
• Secondary ID: JDRF grant numbe
• Status: Recruiting
• Phase: Phase 4
• First received: May 10, 2007
• Last updated: May 10, 2007
• Start date: May 2007

Study information

• Verified date: May 2007
• Source: King's College Hospital NHS Trust
• Contact: Pratik Choudhary, MBBS, MRCP
• Phone: +44 203 299 9000
• Email: pratik.choudhary[@]kcl.ac.uk
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

To see if using medication called sulphonylureas can help improve symptoms which patients rely on to recognise low blood glucose levels ( hypoglycaemia) and also to see if they can reduce the slowing down in brain function which occurs at hypoglycaemia.

Description:

Low blood glucose (hypoglycaemia) is the most common and important side effect of insulin treatment for diabetes. Most episodes are “mild” and lead to symptoms that alert the individual to raise their blood sugar level by consuming sugar or starch (carbohydrate). The body also responds to low blood sugars by producing hormones such as adrenaline and cortisol, which help to restore blood sugar levels to normal. As the brain relies on sugar for fuel, it does not function properly if blood sugar levels drop too low, resulting in confusion and in extreme cases reduced conscious levels.

Repeated hypoglycaemia can blunt the protective symptoms and hormonal responses to hypoglycaemia limiting patients’ ability to recognise and correct hypoglycaemia, putting them at high risk of even more hypoglycaemia (Heller and Cryer, 1991).

Sulphonylureas are tablets used to treat type 2 diabetes that work by stimulating the pancreas to make more insulin. They do this by closing pores called KATP channels which are found on the surface of many cells and control the rate of firing of cells. In the pancreas, closing them causes cells to fire and release insulin. However, in other tissues such as in the brain, these channels have a protective function and they open up during times of lack of fuel, such as lack of oxygen or sugar, preventing the cells from firing and putting them into a resting mode which reduces their energy requirement(Dunn-Meynell, Rawson and Levin 1998). However, if the brain cells responsible for generating symptoms are put into this resting mode, they may not produce symptoms, which may contribute to hypoglycaemia unawareness.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age 18-75

• Type 1 diabetes (WHO definition) of at least 5 years duration

• History of impaired awareness of hypoglycaemia (capillary glucose readings < 3.5mmol/l without symptoms on > 3 occasions in the past 3 months (those with intact symptoms will be unlikely to show an improvement and would not really benefit from taking any medication intended just to increase symptoms)

Exclusion Criteria:

• Pregnancy

• Severe systemic illness

• Active malignancy

• Severe complications of diabetes such as severe visual impairment, severe renal impairment, severe symptomatic autonomic neuropathy

• Untreated ischemic heart disease, recent stroke

• Lactose intolerance ( the placebo will contain lactose)

• Very poor diabetes control (HbA1c > 10%) Liver disease ( increase in ALT / AST > 3x ULN)

• Chronic Kidney Disease stage 4 or 5 ( eGFR < 30ml/min)

• Severe untreated thyroid or adrenal insufficiency ( must be treated and on stable doses for at least 6 weeks)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes Mellitus

Intervention

Drug:
• Glibenclamide

Locations

Country	Name	City	State
United Kingdom	King's College Hospital NHS Foundation Trust	London

Sponsors (1)

Lead Sponsor	Collaborator
King's College Hospital NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glucose threshold for development of symptoms and cognitive impairment due to hypoglycaemia		1 year
Secondary	Improvement in counter regulatory hormone response to hypoglycaemia		1 year